Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis.

Rev Peru Med Exp Salud Publica · 2024 · PMC11152244 · PMID 38808848

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Our NMA showed a trend towards greater efficacy of several treatments than T-DM1 in terms of OS, including T-DXd, T-DM1 combined with atezolizumab, and combinations of pertuzumab, trastuzumab and capecitabine, among others.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.